B7-H3作为肺癌治疗靶点的吸引力。
The Attractiveness of B7-H3 as a Target for Lung Cancer Treatment.
作者信息
Papavassiliou Kostas A, Sofianidi Amalia A, Papavassiliou Athanasios G
机构信息
First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
出版信息
Cancers (Basel). 2025 May 1;17(9):1546. doi: 10.3390/cancers17091546.
Abstract
In 2015, the U [...].
摘要
2015年，美国[……]。 （你提供的原文不完整，我只能翻译到这里。请补充完整原文，以便我给出更准确的译文。）
相似文献
1
The Attractiveness of B7-H3 as a Target for Lung Cancer Treatment.
Cancers (Basel). 2025 May 1;17(9):1546. doi: 10.3390/cancers17091546.
2
B7-H3 promotes metastasis, proliferation, and epithelial-mesenchymal transition in lung adenocarcinoma.
Onco Targets Ther. 2018 Aug 10;11:4693-4700. doi: 10.2147/OTT.S169811. eCollection 2018.
3
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments.
Invest New Drugs. 2023 Apr;41(2):356-364. doi: 10.1007/s10637-023-01353-8. Epub 2023 Apr 10.
4
B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
Int J Biol Sci. 2020 Mar 25;16(11):1767-1773. doi: 10.7150/ijbs.41105. eCollection 2020.
5
B7-H3 Associates with IMPDH2 and Regulates Cancer Cell Survival.
Cancers (Basel). 2023 Jul 7;15(13):3530. doi: 10.3390/cancers15133530.
6
The expression and clinical significance of B7-H3 and miR-145 in lung cancer patients with malignant pleural effusion.
Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6759-6766. doi: 10.26355/eurrev_202006_21664.
7
High expression of B7-H3 on monocyte/macrophages in tumor microenvironment promotes lung cancer progression by inhibiting apoptosis.
Transl Oncol. 2024 Mar;41:101874. doi: 10.1016/j.tranon.2023.101874. Epub 2024 Jan 22.
8
Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
Eur J Cancer. 2020 Jul;133:74-85. doi: 10.1016/j.ejca.2020.03.033. Epub 2020 May 21.
9
B7-H3 regulates lipid metabolism of lung cancer through SREBP1-mediated expression of FASN.
Biochem Biophys Res Commun. 2017 Jan 22;482(4):1246-1251. doi: 10.1016/j.bbrc.2016.12.021. Epub 2016 Dec 7.
10
B7-H3 promotes proliferation and migration of lung cancer cells by modulating PI3K/AKT pathway via ENO1 activity.
Transl Cancer Res. 2024 Feb 29;13(2):833-846. doi: 10.21037/tcr-23-1537. Epub 2024 Feb 15.
本文引用的文献
1
Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications.
Immunotargets Ther. 2025 Mar 27;14:291-320. doi: 10.2147/ITT.S507522. eCollection 2025.
2
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Cancer Res Commun. 2024 May 30;4(5):1369-1379. doi: 10.1158/2767-9764.CRC-23-0546.
3
High expression of B7-H3 on monocyte/macrophages in tumor microenvironment promotes lung cancer progression by inhibiting apoptosis.
Transl Oncol. 2024 Mar;41:101874. doi: 10.1016/j.tranon.2023.101874. Epub 2024 Jan 22.
4
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
Cancer Cell. 2024 Feb 12;42(2):209-224.e9. doi: 10.1016/j.ccell.2023.12.013. Epub 2024 Jan 11.
5
B7-H3/CD276 and small-cell lung cancer: What's new?
Transl Oncol. 2024 Jan;39:101801. doi: 10.1016/j.tranon.2023.101801. Epub 2023 Oct 20.
6
B7H3 targeting gold nanocage pH-sensitive conjugates for precise and synergistic chemo-photothermal therapy against NSCLC.
J Nanobiotechnology. 2023 Oct 17;21(1):378. doi: 10.1186/s12951-023-02078-9.
7
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments.
Invest New Drugs. 2023 Apr;41(2):356-364. doi: 10.1007/s10637-023-01353-8. Epub 2023 Apr 10.
8
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
Mol Cancer. 2023 Mar 2;22(1):43. doi: 10.1186/s12943-023-01751-9.
9
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Nat Med. 2022 Nov;28(11):2374-2380. doi: 10.1038/s41591-022-01977-y. Epub 2022 Aug 25.
10
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
J Immunother Cancer. 2022 Apr;10(4). doi: 10.1136/jitc-2021-004424.
Zotero 插件